Advertisement

Today's Headlines

Safety Profile of Ixazomib in Japanese Patients with Relapsed/Refractory MM

A study published in Internal Medicine evaluated the safety profile of ixazomib in a cohort of Japanese patients with relapsed/refractory multiple myeloma (MM). Ixazomib is a proteasome inhibitor improved in both the US and Japan in combination with other therapies...

How Language Barriers Impact Patient Experiences in Cancer Care

In a randomized trial, researchers sough to determine the impact of patient-provider language agreement and patients’ satisfaction with their cancer care. This study was...

Factors Associated with Palliative Care Use Among Patients with Multiple Myeloma

Several factors are correlated with palliative care use among patients with various cancers, but literature is lacking on multiple myeloma (MM)-specific factors, researchers noted....

Assessing the Impact of COVID-19 Countermeasures in Korean Patients with Lymphoma and Multiple Myeloma

Researchers sought to discern the effect of COVID-19 countermeasures on treatment outcomes in a patient population receiving chemotherapy for lymphoma or multiple myeloma (MM)...

Personalized Sequential Multiple Myeloma Regimen Shows Promise in Older, Frail Patients

In a phase II prospective clinical trial, researchers evaluated the effectiveness of a personalized sequential therapy for older patients with multiple myeloma, developed based...
- Advertisement -

Expert Interviews

Journal Abstracts